Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Invictus MD Strategies Investments Begin To Grow

Apr 11, 2017 • 3:39 PM EDT
Untitled design (87).png
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Today, Invictus MD Strategies Corp. (IMH.V) (IVITF) annoucned that Acreage Pharms’ new cultivation cycle commenced after receiving their license to cultivate under the ACMPR. Invictus MD has the option to acquire 100% of Acreage Pharms and we expect this deal to immediately prove to be accretive.

We are favorable on this development and the acquisition because we expect Invictus to recognize millions worth of synergies over the next few years. Initially, Invictus will benefit by Acreage Pharms utilizing fertilizer from Future Harvest Development throughout the growing process. Invictus currently owns 82.5% of Future Harvest Development.

From the CEO

Invictus MD Chairman and CEO Dan Kriznic said, “We’re very proud that Acreage Pharm’s management team has taken steps to implement quality assurance practices and operational controls at the very beginning to ensure operations are at a world class standard level,” stated We’re all steadfast in our commitment to lead with practices that meet or exceed the regulatory standard for safety and quality in the Canadian cannabis industry.  We are Canada’s Cannabis Company.”

An Execution Story

Earlier this month, Invictus completed its investment in AB Laboratories (33.3%) and now has a 16,000 square-foot facility in Hamilton, Ontario that is licensed to cultivate cannabis under the ACMPR.

Over the next year, AB Labs will be able to significantly increase production capacity through AB Ventures after its acquisition of 100 acres in Ontario (expected to close on May 1st). This property will be used to cultivate cannabis once the company is fully licensed under the ACMPR. 

Earlier this year, Invictus MD signed a definitive option agreement to acquire 100% of OptionCo. In January, OptionCo received its pre-license from Health Canada and expects to receive a license to cultivate under the ACMPR soon. OptionCo’s production facility is located on 150 acres in Alberta.

A Company to Watch

Invictus MD is focused on three verticals within the Canadian cannabis industry and is comprised of three distinct divisions that can create value for each other and improve the value proposition of the entire firm.

We are favorable on its leverage to the cannabis industry due to the attractive operating structure, its stronger balance sheet, and its continued execution. 


Become a Mushroomstocks Premium Member to learn more! 


Important Investor Disclosures 

Disclosure.  Compensated Affiliate.  This report was authored by and is property of Mushroomstocks.  All information and data relied upon in drafting this report is publicly available.  The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by Mushroomstocks regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional advice regarding any and all securities investments.  This report is intended for informational purposes only.  Mushroomstocks’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by Mushroomstocks.  Mushroomstocks may receive compensation from the company and/or has a position in the securities mentioned in this report

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.